Evidence map›Paper›PMID 37696432›Full record

ArticleJournal of vascular and interventional radiology : JVIR2024

Image-Guided Deployment and Monitoring of a Novel Tungsten Nanoparticle-Infused Radiopaque Absorbable Inferior Vena Cava Filter in a Swine Model.

Erin Marie San Valentin, Jossana A Damasco, Marvin Bernardino, Karem A Court, Biana Godin, Gino Martin Canlas, Adam Melancon, Gouthami Chintalapani, Megan C Jacobsen, William Norton and 5 more

Open access · greenAbstract read
In one paragraph

Article in Journal of vascular and interventional radiology : JVIR, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Erin Marie San ValentinDepartment of Interventional Radiology, the University of Texas MD Anderson Cancer Center, Houston, Texas.
Jossana A DamascoDepartment of Interventional Radiology, the University of Texas MD Anderson Cancer Center, Houston, Texas.
Marvin BernardinoDepartment of Interventional Radiology, the University of Texas MD Anderson Cancer Center, Houston, Texas.
Karem A CourtDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, Texas.
Biana GodinDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, Texas.
Gino Martin CanlasDepartment of Chemistry, Lamar University, Beaumont, Texas.
Adam MelanconDepartment of Radiation Physics, the University of Texas MD Anderson Cancer Center, Houston, Texas.
Gouthami ChintalapaniAdvanced Therapies, Siemens Healthineers, Erlangen, Germany.
Megan C JacobsenDepartment of Imaging Physics, the University of Texas MD Anderson Cancer Center, Houston, Texas.
William NortonDepartment of Veterinary Medicine and Surgery, the University of Texas MD Anderson Cancer Center, Houston, Texas.
Rick R LaymanDepartment of Imaging Physics, the University of Texas MD Anderson Cancer Center, Houston, Texas.
Natalie FowlkesDepartment of Veterinary Medicine and Surgery, the University of Texas MD Anderson Cancer Center, Houston, Texas.
Stephen R ChenDepartment of Interventional Radiology, the University of Texas MD Anderson Cancer Center, Houston, Texas.
Steven Y HuangDepartment of Interventional Radiology, the University of Texas MD Anderson Cancer Center, Houston, Texas.
Marites P MelanconDepartment of Interventional Radiology, the University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: mmelancon@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USHouston Methodist · USLamar University · USSiemens Healthineers (Germany) · DE

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Nanoparticle- Infused Radiopaque Absorbable Medical DeviceR01HL141831 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MELANCON, MARITES PASUELO · 2018 to 2022
$1.9M
Biodegradable Radiopaque Polymeric Scaffolds Loaded with Mesenchymal Stem Cells for Image-Guided Arteriovenous Fistula Maturation and Long-Term PatencyR01HL159960 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MELANCON, MARITES PASUELO · 2022 to 2025
$1.6M
NCI NIH HHS P30 CA016672NHLBI NIH HHS R01 HL141831NHLBI NIH HHS R01 HL159960
6 · The paper itself

Abstract

purposeTo improve radiopacity of radiolucent absorbable poly-p-dioxanone (PPDO) inferior vena cava filters (IVCFs) and demostrate their effectiveness in clot-trapping ability. MATERIALS AND

methodsTungsten nanoparticles (WNPs) were incorporated along with polyhydroxybutyrate (PHB), polycaprolactone (PCL), and polyvinylpyrrolidone (PVP) polymers to increase the surface adsorption of WNPs. The physicochemical and in vitro and in vivo imaging properties of PPDO IVCFs with WNPs with single-polymer PHB (W-P) were compared with those of WNPs with polymer blends consisting of PHB, PCL, and PVP (W-PB).

resultsIn vitro analyses using PPDO sutures showed enhanced radiopacity with either W-P or W-PB coating, without compromising the inherent physicomechanical properties of the PPDO sutures. W-P- and W-PB-coated IVCFs were deployed successfully into the inferior vena cava of pig models with monitoring by fluoroscopy. At the time of deployment, W-PB-coated IVCFs showed a 2-fold increase in radiopacity compared to W-P-coated IVCFs. Longitudinal monitoring of in vivo IVCFs over a 12-week period showed a drastic decrease in radiopacity at Week 3 for both filters.

conclusionsThe results highlight the utility of nanoparticles (NPs) and polymers for enhancing radiopacity of medical devices. Different methods of incorporating NPs and polymers can still be explored to improve the effectiveness, safety, and quality of absorbable IVCFs.

Indexed as

NanoparticlesVena Cava FiltersAnimalsDevice RemovalPolymersSwineTungstenVena Cava, InferiorPolymersTungsten

Identifiers

PMID37696432
PMCPMC10872373
OpenAlexW4386575410

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.